EZH2 and neoplasm: MYCN-amplified samples express high levels of the H3K9 histone-lysine methytransferases EHMT and EZH2, which directly contribute to low expression of CXCL9 and CXCL10 and a non-T cell-inflamed phenotype in primary tumor transcriptomic data as well as in human NBL cells, and can be reversed by targeted EHMT and EZH2 inhibitors (52).